2008/07/03 by Leemon B. McHenry, Jon Jureidini · 3 citations
Pharmacology, Toxicology and Pharmaceutics · Decision Sciences · Medicine · #Pharmaceutical industry and healthcare #Meta-analysis and systematic reviews #Ethics in Clinical Research
paper · doi:10.1080/08989620802194384
openalex publication_date 2008/07/03 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/29
In this case study from litigation, we show how ghostwriting of clinical trial results can contribute to the manipulation of data to favor the study medication. Study 329 for paroxetine pediatric use was negative for efficacy and positive for harm. Yet the ghostwritten publication from this study concluded that paroxetine provided evidence of efficacy and safety and continues to be influential. Despite the role of named authors in revisions of the manuscript, the sponsor company remained in control of the message.